Clinical Trials Logo

Plaque Psoriasis clinical trials

View clinical trials related to Plaque Psoriasis.

Filter by:

NCT ID: NCT06108544 Recruiting - Plaque Psoriasis Clinical Trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Start date: November 6, 2023
Phase: Phase 3
Study type: Interventional

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.

NCT ID: NCT06104644 Recruiting - Plaque Psoriasis Clinical Trials

A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)

DELPHIN
Start date: April 13, 2023
Phase:
Study type: Observational

The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period

NCT ID: NCT06088199 Recruiting - Plaque Psoriasis Clinical Trials

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Start date: October 24, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

NCT ID: NCT06088043 Recruiting - Plaque Psoriasis Clinical Trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Start date: November 6, 2023
Phase: Phase 3
Study type: Interventional

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.

NCT ID: NCT06030076 Recruiting - Plaque Psoriasis Clinical Trials

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Start date: September 6, 2023
Phase:
Study type: Observational

The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.

NCT ID: NCT06005532 Recruiting - Plaque Psoriasis Clinical Trials

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Start date: October 2, 2023
Phase: Phase 3
Study type: Interventional

MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®. The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.

NCT ID: NCT05994976 Recruiting - Atopic Dermatitis Clinical Trials

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

Start date: October 17, 2023
Phase:
Study type: Observational

The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.

NCT ID: NCT05913817 Recruiting - Clinical trials for Rheumatoid Arthritis

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

EASE PAIN
Start date: January 9, 2023
Phase:
Study type: Observational

The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market. The phase IV study is an observational, pan-Canadian, multidisciplinary study aiming to enroll 600 patients across 50-70 sites across 3 different Therapeutic Areas (GI, Rheum, Derm).

NCT ID: NCT05835843 Recruiting - Plaque Psoriasis Clinical Trials

Study to Assess the Reliability of PASI Scoring Using Digital-Based Images

Start date: June 2, 2023
Phase:
Study type: Observational

This is an open-labeled study to evaluate the reliability of digital photographs for the remote assessment of the disease severity of plaque psoriasis.

NCT ID: NCT05811234 Recruiting - Plaque Psoriasis Clinical Trials

A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults

PRO-SCALP
Start date: June 13, 2023
Phase:
Study type: Observational

The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of Calcipotriene/Betamethasone Dipropionate (CAL/BDP) PAD cream in a real-world setting.